NSPR Stock Forecast: InspireMD, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for InspireMD, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 73 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores InspireMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (95): Analysts have, on balance, been raising their forecasts.
Momentum (13): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NSPR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NSPR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 11 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 May 2026 | Piper Sandler | Reiterates | Overweight | $4.00 → $3.00 |
| 12 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2024 | Lake Street | Initiates | Buy | — |
| 17 Sept 2024 | Piper Sandler | Reiterates | Overweight | $4.50 |
| 2 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 12 June 2023 | Piper Sandler | Initiates | Overweight | — |
| 17 May 2023 | National Alliance Securities | Maintains | Buy | — |
| 31 Mar 2023 | Alliance Global Partners | Maintains | Buy | — |
| 16 Oct 2020 | Alliance Global Partners | Initiates | Buy | $0.70 |
| 11 Mar 2020 | HC Wainwright & Co. | Reiterates | Buy | $5.00 → $2.00 |
| 29 Mar 2016 | Rodman & Renshaw | Maintains | Buy | $4.00 → $3.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NSPR.
This page is one stock. Monday covers all of them.
NSPR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NSPR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, InspireMD, Inc. returned −68.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NSPR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.2×
- Price / book
- 1.3×
- EV / EBITDA
- —
Cheaper than 34% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- −43.7%
- Operating margin
- —
- Net margin
- —
Higher than 2% of US stocks
- Return on equity
- −115.4%
- Return on assets
- −55.1%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
InspireMD, Inc. has a market value of $33.6M and an enterprise value of $11.7M.
Revenue in the twelve months to 30 June 2026: $10.8M. The latest quarter shrank 0.4% year on year.
Net income over the same four quarters: −$52.5M, a −484.1% net margin.
Diluted earnings per share, trailing twelve months: −$0.64.
Free cash flow in the twelve months to 30 June 2026: −$42.5M.
InspireMD, Inc. employs 127 people — $85K of revenue per employee.
Data provided by Twelve Data
NSPR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NSPR’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own InspireMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NSPR
What is the NSPR stock price forecast for 2026-2027?
The median 12-month analyst price target for InspireMD, Inc. is $3, with estimates ranging from $2 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NSPR stock a buy right now?
Of the 3 analysts covering InspireMD, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InspireMD, Inc. 73 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NSPR?
As at 21 Nov 2026, InspireMD, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).
Will NSPR stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $3, and Ticker Nerd's factor model ranks InspireMD, Inc. 73 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NSPR stock forecast for 2030?
No analyst covering InspireMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $4 over the next 12 months.
How has NSPR stock performed over the past year?
InspireMD, Inc. returned -68.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does InspireMD, Inc. do?
InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions. The company’s portfolio centers on its proprietary CGuard™ carotid stent platform and MicroNet™ mesh technology, which are designed to support embolic protection during and after stenting procedures.
About InspireMD, Inc.
InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions. The company’s portfolio centers on its proprietary CGuard™ carotid stent platform and MicroNet™ mesh technology, which are designed to support embolic protection during and after stenting procedures. InspireMD’s current products include carotid embolic prevention and stent systems used in vascular and neurovascular interventions, with applications across stroke prevention and related artery treatment settings. The company serves physicians, hospitals, and healthcare providers in multiple international markets, including the United States and select regions in Europe, the Middle East, Latin America, and Asia Pacific. InspireMD plays a specialized role in the medical technology market by focusing on device-based solutions for complex carotid and coronary care.
CEO Mr. Marvin L. Slosman · 127 employees · United States · https://www.inspiremd.com